Several European countries are now issuing new guidance for their citizens intending to travel to the United States due to ...

A raft of travel rules are lurking round the corner for Brits travelling to the EU, which have the potential to bamboozle ...

He said this initiative aims to improve the current system, as foreign investors were previously issued social visit passes valid for only 14 to 90 days, depending on their country of origin.

foreign investors were only issued social visit passes valid for 14 to 90 days, depending on their country of origin," he said in a statement on Wednesday (March 12). Applications for the special ...

who are only given social visit passes valid for 14 to 90 days, depending on their home country. He said the investor pass scheme would be implemented through the ministry’s Xpats Gateway ...

Sponsor Message The bill puts significant pressure on Democrats in the Senate whose votes will be needed in order to pass the bill and avoid a shutdown. The federal government runs out of money at ...

The Eurail Global Pass remains one of the most convenient ways to explore Europe, connecting scenic routes and iconic cities across the continent. Now, European rail travel is even more affordable ...

When a planet passes between its star and Earth ... “we can get down to planets that straddle where we think the cosmic shoreline is,” Kempton said, “and map out where that boundary is.” Even though ...

Republicans needed overwhelming support from their members to pass the funding measure, and they got it in the 217-213 House vote. In the Senate, they’ll need support from at least eight ...

Unlimited Epic Passes, valid locally at Stevens Pass and regionally at Whistler Blackcomb, are on sale for $1,051. Cheaper options include a midweek pass ($430) and Epic Local Pass ($783).

If it fails to pass by Friday, when current funding expires, the government will shut down. Failure to pass funding legislation twice led to shutdowns during Trump’s first term, including a ...

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety trial, researchers report in The Lancet, external medical journal.